Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.
Baron F, Zachée P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, Willems E, Emonds MP, De Becker A, Beguin Y. Baron F, et al. Among authors: van gelder m. J Hematol Oncol. 2015 Feb 6;8:4. doi: 10.1186/s13045-014-0098-9. J Hematol Oncol. 2015. PMID: 25652604 Free PMC article. Clinical Trial.
Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.
van Gelder M, de Wreede LC, Schetelig J, van Biezen A, Volin L, Maertens J, Robin M, Petersen E, de Witte T, Kröger N; EBMT Chronic Malignancies Working Party. van Gelder M, et al. Among authors: van biezen a. Leukemia. 2013 Apr;27(4):879-88. doi: 10.1038/leu.2012.297. Epub 2012 Oct 16. Leukemia. 2013. PMID: 23164802
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ. Terwijn M, et al. Among authors: van der velden vh, van putten wl, van gelder m. J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23. J Clin Oncol. 2013. PMID: 24062400 Clinical Trial.
Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.
de Wreede LC, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden CE, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher GM, Herr W, Choquet S, Niederwieser DW, Sutton L, Kröger N, de Witte TM, Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council J. de Wreede LC, et al. Among authors: van gelder m, van os m. Am J Hematol. 2014 Feb;89(2):174-80. doi: 10.1002/ajh.23610. Am J Hematol. 2014. PMID: 24123244 Free article.
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.
van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP. van Gelder M, et al. Among authors: van oers mh. Bone Marrow Transplant. 2016 Jun;51(6):799-806. doi: 10.1038/bmt.2016.9. Epub 2016 Feb 15. Bone Marrow Transplant. 2016. PMID: 26878656 Clinical Trial.
Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.
Servais S, Baron F, Lechanteur C, Seidel L, Selleslag D, Maertens J, Baudoux E, Zachee P, Van Gelder M, Noens L, Kerre T, Lewalle P, Schroyens W, Ory A, Beguin Y. Servais S, et al. Among authors: van gelder m. Oncotarget. 2018 Apr 17;9(29):20590-20604. doi: 10.18632/oncotarget.25020. eCollection 2018 Apr 17. Oncotarget. 2018. PMID: 29755674 Free PMC article.
Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N. Schetelig J, et al. Among authors: van gelder m. Leukemia. 2019 Mar;33(3):686-695. doi: 10.1038/s41375-018-0302-y. Epub 2018 Dec 20. Leukemia. 2019. PMID: 30573777 Free PMC article.
Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
Andersen NS, Bornhäuser M, Gramatzki M, Dreger P, Vitek A, Karas M, Michallet M, Moreno C, van Gelder M, Henseler A, de Wreede LC, Schönland S, Kröger N, Schetelig J; CLL subcommittee, Chronic Malignancies Working Party. Andersen NS, et al. Among authors: van gelder m. J Cancer Res Clin Oncol. 2019 Nov;145(11):2823-2834. doi: 10.1007/s00432-019-03014-x. Epub 2019 Aug 29. J Cancer Res Clin Oncol. 2019. PMID: 31468122
Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation.
Kalin B, van Norden Y, van Gelder M, Breems D, Maertens J, Jongen-Lavrencic M, Broers AEC, Braakman E, Grob T, Zeijlemaker W, Ossenkoppele GJ, Meijer E, Cornelissen JJ. Kalin B, et al. Among authors: van norden y, van gelder m. Blood Adv. 2020 Sep 22;4(18):4430-4437. doi: 10.1182/bloodadvances.2020002074. Blood Adv. 2020. PMID: 32936907 Free PMC article.
196 results